INVELTYS- loteprednol etabonate suspension

Drug Labeling and Warnings

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    INVELTYS is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Dosage Information

    Instill one to two drops of INVELTYS into the affected eye twice daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period.

    2.2 Administration Instructions

    Instruct patient to wash hands well before each use.

    Shake for one to two seconds before using.

    If the patient is using other eye drops in addition to INVELTYS, advise the patient to wait at least 5 minutes between instillation of INVELTYS and other eye drops.

  • 3 DOSAGE FORMS AND STRENGTHS

    Ophthalmic suspension containing loteprednol etabonate 1% (10mg/mL).

  • 4 CONTRAINDICATIONS

    INVELTYS is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Intraocular Pressure (IOP) Increase

    Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, as well as defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, intraocular pressure should be monitored.

    5.2 Cataracts

    Use of corticosteroids may result in posterior subcapsular cataract formation.

    5.3 Delayed Healing

    Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.

    5.4 Bacterial Infections

    Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection.

    5.5 Viral Infections

    Use of corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

    5.6 Fungal Infections

    Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.

    5.7 Risk of Contamination

    Do not to allow the dropper tip to touch any surface, as this may contaminate the suspension.

    5.8 Contact Lens Wear

    The preservative in INVELTYS may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of INVELTYS and may be reinserted 15 minutes following administration.

  • 6 ADVERSE REACTIONS

    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing and secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The most common adverse drug reactions in the clinical trials with INVELTYS were eye pain and posterior capsular opacification, both reported in 1% of patients. These reactions may have been the consequence of the surgical procedure.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    INVELTYS is not absorbed systemically following topical ophthalmic administration and maternal use is not expected to result in fetal exposure to the drug.

    8.2 Lactation

    Risk Summary

    INVELTYS is not absorbed systemically by the mother following topical ophthalmic administration, and breastfeeding is not expected to result in exposure of the child to INVELTYS.

    8.4 Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    8.5 Geriatric Use

    No overall differences in safety and effectiveness have been observed between elderly and younger patients.

  • 11 DESCRIPTION

    Loteprednol etabonate is a corticosteroid. Its chemical name is chloromethyl 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylate. Its molecular formula is C24H31ClO7 and its chemical structure is:

    Molecule

    C24H31ClO7
    Mol. Wt. 467.0

    INVELTYS (loteprednol etabonate ophthalmic suspension) 1% contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. Each mL contains:

    • ACTIVE: loteprednol etabonate 10 mg (1%)
    • INACTIVES: glycerin, sodium citrate dihydrate, Poloxamer 407, sodium chloride, edetate disodium dihydrate, citric acid, and water for injection
    • PRESERVATIVE: benzalkonium chloride 0.01%
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not clearly established. However, corticosteroids are thought to inhibit prostaglandin production through several independent mechanisms.

    12.3 Pharmacokinetics

    Loteprednol etabonate is lipid soluble and can penetrate into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon in vivo and in vitro preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to inactive carboxylic acid metabolites, PJ-91 and PJ-90.

    Following twice-daily unilateral topical ocular dosing of INVELTYS for 14 days in healthy subjects, the plasma concentrations of loteprednol etabonate were below the limit of quantitation (1 ng/mL) at all timepoints.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic in vitro in the Ames test, the mouse lymphoma thymidine kinase (tk) assay, or in a chromosome aberration test in human lymphocytes, or in vivo in the single dose mouse micronucleus assay.

  • 14 CLINICAL STUDIES

    Clinical efficacy was evaluated in 2 multi-centered, randomized, double-masked, placebo-controlled trials in which patients with an anterior cell grade greater than or equal to "2" (a cell count of 6 or higher using a slit-lamp biomicroscope) after cataract surgery were assigned to INVELTYS or placebo (vehicle) following surgery (NCT # 02163824 and NCT # 02793817). One to two drops of INVELTYS or vehicle was self-administered twice a day for 14 days, beginning the day after surgery. Complete resolution of inflammation (a cell count of 0 maintained through day 15 without rescue medication) and complete resolution of pain (a patient-reported pain grade of 0 maintained through day 15 without rescue medication) was assessed 4, 8, and 15 days post-surgery. In the intent-to-treat analysis of both studies, a significant benefit was seen in the INVELTYS-treated group for complete resolution of ocular inflammation at Days 8 and 15, and complete resolution of pain at Days 4, 8, and 15, when compared with placebo. The consolidated clinical trial results are provided below.

    Figure 1 Consolidated Clinical Trial Data: Percent of Patients with Complete Resolution of Anterior Chamber Cells (Cell Count = 0) at Days 8 and 15

    Figure 1

    * p-values < 0.01 for treatment comparisons

    Figure 2 Consolidated Clinical Trial Data: Percent of Patients Who Were Pain Free at Days 4, 8, and 15

    Figure 2

    * p-values < 0.01 for treatment comparisons

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    INVELTYS (loteprednol etabonate ophthalmic suspension) 1% is a sterile ophthalmic suspension. It is supplied in a white low-density polyethylene bottle, with a natural low-density polyethylene tip, a pink polypropylene cap and a tamper-evident seal imprinted around the neck in the following size:

    2.8 mL in a 5 mL bottle (NDC: 0065-9307-04)

    Storage and Handling

    Do not use if tamper-evident seal is damaged

    Store upright at 15°C to 25°C (59°F to 77°F). Do not freeze.

  • 17 PATIENT COUNSELING INFORMATION

    Administration

    Instruct the patient to shake the bottle for one to two seconds before using. If the patient is using other eye drops in addition to INVELTYS, advise the patient to wait at least 5 minutes between instillation of INVELTYS and other eye drops.

    Risk of Contamination

    Advise patients to wash their hands well before each use. Advise patients not to allow the dropper tip to touch any surface, as this may contaminate the suspension.

    Risk of Secondary Infection

    Advise the patient to consult a physician if pain develops, or redness, itching, or inflammation becomes aggravated.

    Contact Lens Wear

    Advise patients that the preservative in INVELTYS may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of INVELTYS and may be reinserted after 15 minutes following administration.

    U.S. Pat.: www.alconpatents.com

    Manufactured by:

    Alcon Laboratories, Inc.
    Fort Worth, TX 76134 USA

    1-800-757-9195

    Alcon.medinfo@alcon.com

    © 2026 Alcon Inc.

  • INSTRUCTIONS FOR USE

    INVELTYS [in-vel-tis]

    (loteprednol etabonate ophthalmic suspension) 1%

    for topical ophthalmic use

    This Instructions for Use contains information on how to properly administer INVELTYS.

    Important Information You Need to Know Before Using INVELTYS

    • INVELTYS is for use in the eye only.
    • Wash your hands before using INVELTYS.
    • Do not use if the tamper-evident seal is not intact.
    • Do not let the INVELTYS dropper tip touch your eye, fingers, or any other surfaces to avoid contamination or injury to your eye.
    • Use INVELTYS exactly as your healthcare provider tells you to.
    • If you are using INVELTYS with other eye (ophthalmic) medicines, you should wait at least 5 minutes between using INVELTYS and the other medicine.
    • If you wear contact lenses, remove them before using INVELTYS.
    • Put the pink cap back on INVELTYS after each use.

    Follow Steps 1 to 6 each time you use INVELTYS.

    Step 1:Wash your hands well.
    Step 2:Shake the INVELTYS bottle for 1 to 2 seconds (See Figure A)
    .Figure A
                          Figure A
    Step 3:Remove the pink cap from the top of the INVELTYS dropper by turning it counterclockwise (See Figure B). Keep the pink cap. Do not let the INVELTYS dropper tip touch your eye, fingers, or any other surface.

    Figure B
                                                Figure B
    Step 4:Turn the INVELTYS bottle upside down (See Figure C).

    Figure C
                                             Figure C
    Step 5:Tilt your head back. Hold the bottle directly above your affected eye. Squeeze the middle of the INVELTYS bottle gently to put 1 to 2 drops (follow your doctor’s recommendation) into the affected eye (See Figure D).

    Figure D
                                       Figure D
    Step 6:Place the pink cap back onto the INVELTYS bottle and tighten by turning clockwise (See Figure E).

    Figure E
                                        Figure E

    If you use contact lenses, wait for 15 minutes before placing them back in.

    How should I store INVELTYS?

    • Store INVELTYS upright at 59ºF to 77ºF (15ºC to 25ºC).
    • Do not freeze

    Keep INVELTYS and all medicines out of the reach of children.

    This Instructions for Use has been approved by the U.S. Food and Drug Administration.

    Manufactured by:

    Alcon Laboratories, Inc.
    Fort Worth, TX 76134 USA

    Revised: 04/2026

    300074560-1125

  • PRINCIPAL DISPLAY PANEL - 2.8 mL Bottle Carton

    NDC: 0065-9307-04
    Rx Only

    INVELTYS®

    (loteprednol etabonate ophthalmic suspension)1%

    Sterile

    2.8 mL

    NDC: 0065-9307-04
    Rx Only

    INVELTYS®
    (loteprednol etabonate
    ophthalmic suspension) 1%

    FOR TOPICAL
    APPLICATION IN THE EYE.

    Sterile
    2.8 mL

    Alcon

    Dosage: See Prescribing
    Information.

    SHAKE FOR 1 to 2 SECONDS

    Storage: Store upright at 1
    5°C to 25°C (59°F to 77°F).

    DO NOT FREEZE.

    DO NOT USE IF
    TAMPER-EVIDENT
    SEAL IS DAMAGED

    300074557-1125

    Store upright

    28mL-carton

    INVELTYS®
    (loteprednol etabonate
    ophthalmic suspension) 1%

    NDC: 0065-9307-04   Rx Only

    2.8mL

    Sterile

    Alcon Laboratories, Inc.
    Fort Worth, Texas 76134 USA

    300074563-1125

    2.8mL-label
  • PRINCIPAL DISPLAY PANEL - 2.8 mL Bottle Carton

    NDC: 0065-9307-04
    Rx Only

    INVELTYS®

    (loteprednol etabonate ophthalmic suspension)1%

    Sterile

    2.8 mL

    NDC: 0065-9307-05
    Rx Only

    INVELTYS®
    (loteprednol etabonate
    ophthalmic suspension) 1%

    FOR TOPICAL
    APPLICATION IN THE EYE.

    PROFESSIONAL SAMPLE

    Not for Retail Sale

    Sterile
    2.8 mL

    Alcon

    Dosage: See Prescribing
    Information.

    SHAKE FOR 1 to 2 SECONDS

    Storage: Store upright at
    15°C to 25°C (59°F to 77°F).

    DO NOT FREEZE.

    DO NOT USE IF
    TAMPER-EVIDENT
    SEAL IS DAMAGED

    300074556-1125

    Store upright

    sample-carton

    INVELTYS®
    (loteprednol etabonate
    ophthalmic suspension) 1%

    NDC: 0065-9307-05

    Sample

    Rx Only

    2.8mL

    Sterile

    Alcon Laboratories, Inc.
    Fort Worth, Texas 76134 USA
    300074565-1125

    sample-label
  • INGREDIENTS AND APPEARANCE
    INVELTYS 
    loteprednol etabonate suspension
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0065-9307
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Loteprednol Etabonate (UNII: YEH1EZ96K6) (Loteprednol - UNII:Z8CBU6KR16) Loteprednol Etabonate10 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    Glycerin (UNII: PDC6A3C0OX)  
    Trisodium Citrate Dihydrate (UNII: B22547B95K)  
    Sodium Chloride (UNII: 451W47IQ8X)  
    Edetate Disodium (UNII: 7FLD91C86K)  
    Citric Acid Monohydrate (UNII: 2968PHW8QP)  
    Water (UNII: 059QF0KO0R)  
    Benzalkonium Chloride (UNII: F5UM2KM3W7)  
    Anhydrous Citric Acid (UNII: XF417D3PSL)  
    Poloxamer 407 (UNII: TUF2IVW3M2)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0065-9307-041 in 1 CARTON04/16/2026
    12.8 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product
    2NDC: 0065-9307-051 in 1 CARTON04/16/2026
    22.8 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA21056504/16/2026
    Labeler - Alcon Laboratories, Inc. (008018525)
    Establishment
    NameAddressID/FEIBusiness Operations
    Alcon Research LLC007672236manufacture(0065-9307)
    Establishment
    NameAddressID/FEIBusiness Operations
    Industriale Chimica SRL436796809api manufacture(0065-9307)
    • © 2026 FDA.report
    This site is not affiliated with or endorsed by the FDA.